The US Department of Health and Human Services (HHS) Office of Inspector General (OIG) recently concluded that certain intraoperative neuromonitoring (IONM) services arrangements are capable of generating prohibited remuneration under federal laws. The findings were part of OIG’s release of Advisory Opinion No. 23-05.
This evaluation, which took a deep dive into the formation and operation of surgeon-owned entities intended for the provision of IONM services, illustrates OIG’s keen eye for potential fraud risks. This stance discourages IONM service provider’s aid to surgeons in setting up their turnkey businesses. The concern here is that such arrangements could form a gateway for financial kickbacks and incentives, which breach federal laws.
IONM services are essential in the medical field as they assist medical practitioners in reducing the risk of patient injuries that could occur during surgical procedures. However, it’s clear from OIG’s advisory opinion that the office is increasingly focusing on the financial relationships and exchanges in the provision of these services, with particular attention to potential violations of anti-kickback regulations.
Certain IONM arrangements were reviewed by the OIG for their potential to generate illegal remunerations, commonly associated with financial bonuses or benefits that could influence medical practitioners’ decision-making process in treatment plans, choice of medical products or services, among other things. As such, medical and legal professionals working in this area must be conversant with, and strictly adhere to, the professional and legal guidelines to prevent contravention of these laws.
All in all, this recent opinion underscores the need for healthcare providers and legal professionals to exercise caution when engaging in or advising on IONM contracts and businesses. It is necessary to carefully navigate the framework of such arrangements and contracts in order to avoid legal pitfalls. The decision from OIG serves as a reminder of the importance of healthcare compliance in preventing potentially costly, and reputation-damaging, disputes and regulatory penalties.